AB Corporate Bond ETF (NASDAQ:EYEG) Shares Cross Below 200 Day Moving Average – Time to Sell?

AB Corporate Bond ETF (NASDAQ:EYEG) shares passed below its two hundred day moving average during trading on Thursday . The stock has a two hundred day moving average of $35.33 and traded as low as $34.56. AB Corporate Bond ETF shares last traded at $34.56, with a volume of 1,723 shares traded.

AB Corporate Bond ETF Stock Down 0.4%

The company has a debt-to-equity ratio of 0.01, a current ratio of 3.07 and a quick ratio of 3.07. The stock’s fifty day simple moving average is $35.03 and its 200-day simple moving average is $35.33. The stock has a market cap of $27.65 million, a P/E ratio of -20.57 and a beta of 0.18.

AB Corporate Bond ETF Increases Dividend

The business also recently declared a monthly dividend, which was paid on Thursday, August 6th. Stockholders of record on Monday, August 3rd were given a dividend of $0.1427 per share. This represents a c) dividend on an annualized basis and a dividend yield of 5.0%. The ex-dividend date was Monday, August 3rd. This is a positive change from AB Corporate Bond ETF’s previous monthly dividend of $0.14. AB Corporate Bond ETF’s payout ratio is currently -102.38%.

Institutional Trading of AB Corporate Bond ETF

An institutional investor recently bought a new position in AB Corporate Bond ETF stock. Jane Street Group LLC acquired a new position in shares of AB Corporate Bond ETF (NASDAQ:EYEG) in the second quarter, according to its most recent 13F filing with the SEC. The institutional investor acquired 6,496 shares of the specialty pharmaceutical company’s stock, valued at approximately $232,000. Jane Street Group LLC owned about 0.87% of AB Corporate Bond ETF at the end of the most recent reporting period. Institutional investors and hedge funds own 64.16% of the company’s stock.

About AB Corporate Bond ETF

EyeGate Pharmaceuticals, Inc is a clinical stage specialty pharmaceutical company, which engages in the development and commercialization of products for treating diseases and disorders of the eye. Its pipeline includes MoxiGel and Ocular Bandage Gel. The company was founded in 1998 and is headquartered in Waltham, MA.